A BILL 
To establish a program to develop antimicrobial innovations 
targeting the most challenging pathogens and most 
threatening infections. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as ‘‘The Pioneering Anti-
4
microbial Subscriptions To End Up surging Resistance 
5
Act of 2020’’ or ‘‘The PASTEUR Act’’. 
6
23:19 Dec 21, 2020
H8920
2 
•HR 8920 IH
SEC. 2. ESTABLISHMENT OF COMMITTEE; SUBSCRIPTION 
1
MODEL; ADVISORY GROUP. 
2
(a) IN GENERAL.—Not later than 60 days after the 
3
date of enactment of this Act, the Secretary shall establish 
4
a Committee on Critical Need Antimicrobials and appoint 
5
members to the Committee. 
6
(b) MEMBERS.— 
7
(1) IN GENERAL.—The Committee shall consist 
8
of at least one representative from each of the Na-
9
tional Institute of Allergy and Infectious Diseases, 
10
the Centers for Disease Control and Prevention, the 
11
Biomedical Advanced Research and Development 
12
Authority, the Food and Drug Administration, the 
13
Centers for Medicare & Medicaid Services, the Vet-
14
erans Health Administration, and the Department of 
15
Defense. 
16
(2) CHAIR.—The Secretary shall appoint one of 
17
the members of the Committee to serve as the Chair 
18
of the Committee. 
19
(c) DUTIES.—Not later than 1 year after the appoint-
20
ment of all initial members of the Committee, the Sec-
21
retary, in collaboration with the Committee, and in con-
22
sultation with the Critical Need Antimicrobials Advisory 
23
Group established under subsection (g), shall do the fol-
24
lowing: 
25
23:19 Dec 21, 2020
H8920
3 
•HR 8920 IH
(1) Develop a list of prioritized infections for 
1
which new antimicrobial drug development is needed, 
2
taking into account infections for which there is an 
3
unmet medical need, findings from the most recent 
4
report entitled ‘‘Antibiotic Resistance Threats in the 
5
United States’’ issued by the Centers for Disease 
6
Control and Prevention, or an anticipated unmet 
7
medical need. For the list developed under this para-
8
graph, the Secretary, in collaboration with the Com-
9
mittee, may use the infection list in such most re-
10
cent report for up to 3 years following the date of 
11
enactment of this Act and subsequently update the 
12
list under this paragraph in accordance with sub-
13
section (e). 
14
(2) Develop regulations, in accordance with 
15
subsection (d), outlining favored characteristics of 
16
critical need antimicrobial drugs, that are evidence 
17
based, clinically focused, and designed to treat the 
18
infections described in paragraph (1), and estab-
19
lishing criteria for how each such characteristic will 
20
adjust the monetary value of a subscription contract 
21
awarded under subsection (f) or section 4. The fa-
22
vored characteristics shall be weighed for purposes 
23
of such monetary value such that meeting certain 
24
characteristics, or meeting more than one such char-
25
23:19 Dec 21, 2020
H8920
4 
•HR 8920 IH
acteristic, increases the monetary value. Such fa-
1
vored characteristics of an antimicrobial drug shall 
2
include— 
3
(A) treating infections on the list under 
4
paragraph (1); 
5
(B) improving clinical outcomes for pa-
6
tients with multi-drug resistant infections; 
7
(C) being a first-approved drug that treats 
8
certain multi-drug resistant infections, and, to a 
9
lesser extent, second and third drugs that treat 
10
such infections; 
11
(D) addressing an infection located in an 
12
organ or other location that is challenging to 
13
treat; 
14
(E) addressing a multi-drug resistant in-
15
fection through a novel chemical scaffold or 
16
mechanism of action, especially through oral 
17
administration; 
18
(F) having received a transitional subscrip-
19
tion contract under subsection (f); and 
20
(G) any other characteristic the Secretary, 
21
in collaboration with the Committee, determines 
22
necessary. 
23
(d) REGULATIONS.— 
24
23:19 Dec 21, 2020
H8920
5 
•HR 8920 IH
(1) IN GENERAL.—Not later than 1 year after 
1
the appointment of the initial members of the Com-
2
mittee, the Secretary shall issue proposed regula-
3
tions which shall include— 
4
(A) a process by which the sponsors can 
5
apply for an antimicrobial drug to become a 
6
critical need antimicrobial drug under section 3; 
7
(B) how subscription contracts under such 
8
section shall be established and paid; 
9
(C) the favored characteristics under sub-
10
section (c)(2), how such characteristics will be 
11
weighed, and the minimum number and kind of 
12
favored characteristics needed for an anti-
13
microbial drug to be designated a critical need 
14
antimicrobial drug; and 
15
(D) other elements of the subscription con-
16
tract process, in accordance with this Act. 
17
(2) DEVELOPMENT OF FINAL REGULATIONS.— 
18
Before finalizing the regulations under paragraph 
19
(1), the Secretary shall solicit public comment and 
20
hold public meetings for the period beginning on the 
21
date on which the proposed regulations are issued 
22
and ending on the date that is 120 days after such 
23
date of issuance, and shall finalize and publish the 
24
23:19 Dec 21, 2020
H8920
6 
•HR 8920 IH
regulations 60 days after the close of such period of 
1
public comment and meetings. 
2
(3) SUBSCRIPTION
CONTRACT
OFFICE.—Not 
3
later than 6 months after the date of enactment of 
4
this Act, the Secretary shall propose an agency or 
5
office in the Department of Health and Human 
6
Services to manage the establishment and payment 
7
of subscription contracts awarded under section 4, 
8
including eligibility, requirements, and contract 
9
amounts. The Secretary shall solicit public comment 
10
and finalize the agency or office no later than 45 
11
days following the proposed agency or office. 
12
(e) LIST OF INFECTIONS.—The Secretary, in collabo-
13
ration with the Committee, shall update the list of infec-
14
tions under subsection (c)(1) at least every 2 years. 
15
(f) TRANSITIONAL SUBSCRIPTION CONTRACTS.— 
16
(1) IN
GENERAL.—Not earlier than 30 days 
17
after the date of enactment of this Act and ending 
18
on the date that the Secretary finalizes the subscrip-
19
tion contract regulations under subsection (d), the 
20
Secretary may use up to $1,000,000,000 of the 
21
amount appropriated under section 6(a) to engage in 
22
transitional subscription contracts of up to 3 years 
23
in length with antimicrobial developers, as deter-
24
mined by the Secretary, that have developed anti-
25
23:19 Dec 21, 2020
H8920
7 
•HR 8920 IH
microbial drugs treating infections listed in the most 
1
recent report entitled ‘‘Antibiotic Resistance Threats 
2
in the United States’’ issued by the Centers for Dis-
3
ease Control and Prevention, and may include anti-
4
microbial drugs that are qualified infectious disease 
5
products (as defined in section 505E(g) of the Fed-
6
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
7
355f(g))), similarly innovative biologic antimicrobial 
8
drugs, or innovative drugs that achieve an anti-
9
microbial 
outcome 
through 
immunomodulation. 
10
Funds made available under such contracts may be 
11
used for a variety of purposes including to support 
12
the completion of postmarketing clinical studies, 
13
manufacturing, and other preclinical and clinical ef-
14
forts. 
15
(2) REQUIREMENTS.— 
16
(A) IN GENERAL.—The Secretary, through 
17
the office described in paragraph (4), may enter 
18
into a contract under paragraph (1)— 
19
(i) if the Secretary determines that 
20
the antimicrobial drug demonstrates a sig-
21
nificant clinical advancement in treating an 
22
infection for which there is an unmet clin-
23
ical need, an anticipated clinical need, or 
24
multidrug resistance; 
25
23:19 Dec 21, 2020
H8920
8 
•HR 8920 IH
(ii) subject to terms including— 
1
(I) that the Secretary shall cease 
2
any payment installments under a 
3
transitional subscription contract if 
4
the sponsor does not— 
5
(aa) ensure commercial and 
6
Federal availability of the anti-
7
microbial drug within 30 days of 
8
receiving first payment under the 
9
contract; 
10
(bb) identify, track, and 
11
publicly report drug resistance 
12
data and trends using available 
13
data related to the antimicrobial 
14
drug; 
15
(cc) develop and implement 
16
education and communications 
17
strategies, including communica-
18
tions for individuals with limited 
19
English proficiency and individ-
20
uals with disabilities, for health 
21
care professionals and patients 
22
about appropriate use of the 
23
antimicrobial drug; 
24
23:19 Dec 21, 2020
H8920
9 
•HR 8920 IH
(dd) submit a plan for reg-
1
istering the antimicrobial drug in 
2
additional countries where an 
3
unmet medical need exists; 
4
(ee) subject to subparagraph 
5
(B), ensure a reliable drug sup-
6
ply chain, thus leading to an 
7
interruption of the supply of the 
8
antimicrobial drug in the United 
9
States for more than 60 days; or 
10
(ff) 
make 
meaningful 
11
progress toward completion of 
12
Federal Drug Administration-re-
13
quired postmarketing studies, in-
14
cluding such studies that are evi-
15
dence based; and 
16
(II) other terms as determined by 
17
the Secretary; and 
18
(iii) if— 
19
(I) a phase 3 clinical study has 
20
been initiated for the antimicrobial 
21
drug; or 
22
(II) the antimicrobial drug has 
23
been approved under section 505(c) of 
24
the Federal Food, Drug, and Cos-
25
23:19 Dec 21, 2020
H8920
10 
•HR 8920 IH
metic Act (21 U.S.C. 355(c)) or li-
1
censed under section 351(a) of the 
2
Public Health Service Act (42 U.S.C. 
3
262(a)). 
4
(B) WAIVER.—The requirement under sub-
5
paragraph (A)(ii)(I)(ee) may be waived in the 
6
case that an emergency prohibits access to a re-
7
liable drug supply chain. 
8
(3) TRANSITIONAL GUIDANCE.—Not later than 
9
30 days after the appointment of the initial mem-
10
bers of the Committee, the Secretary shall issue, in 
11
consultation with the Committee, transitional guid-
12
ance outlining the antimicrobial drugs that are eligi-
13
ble for transitional subscription contracts under 
14
paragraph (1), the requirements to enter into a 
15
transitional subscription contract under paragraph 
16
(2), and the process by which drug developers can 
17
enter into transitional subscription contracts with 
18
the Secretary under this subsection. 
19
(4) PAYMENT OFFICE AND MECHANISM.—Not 
20
later than 30 days after the date of enactment of 
21
this Act, the Secretary shall determine the agency or 
22
office in the Department of Health and Human 
23
Services that will manage the transitional subscrip-
24
tion contracts, including eligibility, requirements, 
25
23:19 Dec 21, 2020
H8920
11 
•HR 8920 IH
and contract amounts, during the period described 
1
in paragraph (1). 
2
(g) CRITICAL
NEED
ANTIMICROBIAL
ADVISORY 
3
GROUP.— 
4
(1) IN GENERAL.—Not later than 30 days after 
5
the appointment of all initial members of the Com-
6
mittee, the Secretary, in collaboration with the Com-
7
mittee, shall establish a Critical Need Antimicrobial 
8
Advisory Group (referred to in this subsection as the 
9
‘‘Advisory Group’’) and appoint members to the Ad-
10
visory Group. 
11
(2) MEMBERS.—The members of the Advisory 
12
Group shall include— 
13
(A) 6 individuals who are— 
14
(i) infectious disease specialists; or 
15
(ii) other health experts with expertise 
16
in researching antimicrobial resistance, 
17
health economics, or commercializing anti-
18
microbial drugs; and 
19
(B) not less than 5 patient advocates. 
20
(3) CHAIR.—The Secretary shall appoint one of 
21
the members of the Advisory Group to serve as the 
22
Chair. 
23
(4) CONFLICTS OF INTEREST.—In appointing 
24
members under paragraph (2), the Secretary shall 
25
23:19 Dec 21, 2020
H8920
12 
•HR 8920 IH
ensure that no member receives compensation in any 
1
manner from a commercial or for-profit entity that 
2
develops antimicrobials or that might benefit from 
3
antimicrobial development. 
4
(5) APPLICABILITY OF FACA.—Except as other-
5
wise provided in this subsection, the Federal Advi-
6
sory Committee Act (5 U.S.C. App.) shall apply to 
7
the Advisory Group. 
8
SEC. 3. CRITICAL NEED ANTIMICROBIAL DRUG APPLICA-
9
TION AND PAYMENT THROUGH SUBSCRIP-
10
TION CONTRACTS. 
11
(a) IN GENERAL.— 
12
(1) SUBMISSION OF REQUEST.—The sponsor of 
13
an application under section 505(b) of the Federal 
14
Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) 
15
or section 351(a) of the Public Health Service Act 
16
(42 U.S.C. 262(a)) for an antimicrobial drug may 
17
request that the Secretary designate the drug as a 
18
critical need antimicrobial. A request for such des-
19
ignation may be submitted after the Secretary 
20
grants for such drug an investigational new drug ex-
21
emption under section 505(i) of the Federal Food, 
22
Drug, and Cosmetic Act or section 351(a)(3) of the 
23
Public Health Service Act, and shall be submitted 
24
not later than 5 years after the date of approval 
25
23:19 Dec 21, 2020
H8920
13 
•HR 8920 IH
under section 505(c) of the Federal Food, Drug, and 
1
Cosmetic Act or licensure under section 351(a) of 
2
the Public Health Service Act. 
3
(2) CONTENT OF REQUEST.—A request under 
4
paragraph (1) shall include information, such as 
5
clinical, preclinical and postmarketing data, a list of 
6
the favorable characteristics described in section 
7
2(c)(2), and any other material that the Secretary in 
8
consultation with the Committee requires. 
9
(3) REVIEW
BY
SECRETARY.—The Secretary 
10
shall promptly review all requests for designation 
11
submitted under this subsection, assess all required 
12
application components, and determine if the anti-
13
microbial drug is likely to meet the favorable charac-
14
teristics identified in the application upon the com-
15
pletion of clinical development. After review, the Sec-
16
retary shall approve or deny each request for des-
17
ignation no later than 90 days after receiving a re-
18
quest. If the Secretary approves a request, it shall 
19
publish the value of the contract that the critical 
20
need antimicrobial developer would be eligible to re-
21
ceive if such developer successfully demonstrates 
22
that the drug meets the maximum value of the fa-
23
vored characteristics listed in the application. 
24
23:19 Dec 21, 2020
H8920
14 
•HR 8920 IH
(4) LENGTH OF DESIGNATION PERIOD.—A des-
1
ignation granted under this section shall be in effect 
2
for a period of 10 years after the date that the des-
3
ignation is approved, and shall remain in effect for 
4
such period even if the infection treated by such 
5
drug is later removed from the list of infections 
6
under section 2(c)(1). 
7
(5) SUBSEQUENT REVIEWS.—No sooner than 2 
8
years after a designation approval or denial under 
9
subsection (3), the sponsor may request a subse-
10
quent review to re-evaluate the value of a contract 
11
to include any new information. 
12
(b) DEVELOPMENT OF DESIGNATED DRUGS.—If a 
13
critical need antimicrobial designation is granted during 
14
clinical development of an antimicrobial drug, the Sec-
15
retary may work with the sponsor to maximize the oppor-
16
tunity for the sponsor to successfully demonstrate that the 
17
antimicrobial drug possesses the favored characteristics of 
18
high-monetary valued products identified under section 
19
2(c)(2). 
20
(c) APPROPRIATE USE OF CRITICAL NEED ANTI-
21
MICROBIAL.— 
22
(1) IN
GENERAL.—The sponsor of an anti-
23
microbial drug that receives designation under sub-
24
section (a) shall submit an appropriate use plan to 
25
23:19 Dec 21, 2020
H8920
15 
•HR 8920 IH
the Secretary within 90 days of application approval 
1
for appropriate use of diagnostics for consideration 
2
by the Secretary and Committee to develop clinical 
3
guidelines. A diagnostic plan— 
4
(A) shall include— 
5
(i) the appropriate use of the drug; 
6
and 
7
(ii) the appropriate use of diagnostic 
8
tools such as diagnostic testing for bio-
9
markers related to antimicrobial-resistant 
10
pathogens, or other targeted diagnostic ap-
11
proaches, to inform use of the drug; and 
12
(B) may be developed in partnership with 
13
the Secretary, infectious disease experts, diag-
14
nostic experts, or another entity. 
15
(2) CONSULTATION.—The Secretary shall work 
16
with relevant professional societies and the Critical 
17
Need Antimicrobial Advisory Group established 
18
under section 2(g) to ensure that clinical guidelines 
19
issued by the Secretary under paragraph (3), with 
20
respect to an antimicrobial drug designated under 
21
subsection (a), includes the use of appropriate diag-
22
nostic approaches, taking into consideration the di-
23
agnostic plan submitted by a sponsor under para-
24
graph (1). 
25
23:19 Dec 21, 2020
H8920
16 
•HR 8920 IH
(3) PUBLICATION OF CLINICAL GUIDELINES.— 
1
Not later than 1 year after the Secretary makes the 
2
first designation under subsection (a), and not less 
3
than every 3 years thereafter, the Secretary shall 
4
publish clinical guidelines in collaboration with rel-
5
evant professional societies with respect to each anti-
6
microbial drug designated under subsection (a) 
7
which shall set forth the evidence-based rec-
8
ommendations for prescribing the drug, in accord-
9
ance with the submissions of the sponsor under 
10
paragraph (1) and after consultation under para-
11
graph (2), as appropriate. 
12
SEC. 4. SUBSCRIPTION CONTRACTS. 
13
(a) APPLICATION
FOR
A
SUBSCRIPTION
CON-
14
TRACT.— 
15
(1) SUBMISSION OF APPLICATIONS.—After ap-
16
proval under section 505(c) of the Federal Food, 
17
Drug, and Cosmetic Act (21 U.S.C. 355(c)) or licen-
18
sure under section 351(a) of the Public Health Serv-
19
ice Act (42 U.S.C. 262(a)), the sponsor of an anti-
20
microbial drug designated as a critical need anti-
21
microbial under section 3 may submit an application 
22
for a subscription contract with the Secretary, under 
23
a procedure established by the Secretary. 
24
23:19 Dec 21, 2020
H8920
17 
•HR 8920 IH
(2) REVIEW OF APPLICATIONS.—The Secretary 
1
shall, in consultation with the Committee— 
2
(A) review all applications for subscription 
3
contracts under paragraph (1) and assess all 
4
required application components; 
5
(B) determine the extent to which the crit-
6
ical need antimicrobial meets the favored char-
7
acteristics identified under section 2(c)(2), and 
8
deny any application for a drug that meets 
9
none of such characteristics; and 
10
(C) assign a monetary value to the con-
11
tract based on the regulations developed under 
12
section 2(d). 
13
(b) CRITERIA.—To qualify for a subscription contract 
14
under this section, the sponsor of an antimicrobial drug 
15
designated as a critical need antimicrobial shall agree to— 
16
(1) ensure commercial and Federal availability 
17
of the antimicrobial drug within 30 days of receiving 
18
first payment under the contract, and sufficient sup-
19
ply for susceptibility device manufacturers; 
20
(2) identify, track, and publicly report drug re-
21
sistance data and trends using available data related 
22
to the antimicrobial drug; 
23
(3) develop and implement education and com-
24
munications strategies, including communications 
25
23:19 Dec 21, 2020
H8920
18 
•HR 8920 IH
for individuals with limited English proficiency and 
1
individuals with disabilities, for health care profes-
2
sionals and patients about appropriate use of the 
3
antimicrobial drug; 
4
(4) submit an appropriate use assessment to 
5
the Secretary, Committee, Food and Drug Adminis-
6
tration, and Centers for Disease Control and Pre-
7
vention every 2 years regarding use of the anti-
8
microbial drug, including how the drug is being mar-
9
keted; 
10
(5) submit a plan for registering the drug in 
11
additional countries where an unmet medical need 
12
exists; 
13
(6) ensure a reliable drug supply chain, where 
14
any interruption to the supply chain will not last for 
15
more than 60 days in the United States; 
16
(7) complete any postmarketing studies re-
17
quired by the Food and Drug Administration in a 
18
timely manner; 
19
(8) produce the drug at a reasonable volume de-
20
termined with the Secretary to ensure patient access 
21
to the drug; 
22
(9) price the drug at a price that is not lower 
23
than a comparable generic drug; and 
24
23:19 Dec 21, 2020
H8920
19 
•HR 8920 IH
(10) abide by other terms as the Secretary may 
1
require. 
2
(c) TERM AND AMOUNT OF CONTRACTS.— 
3
(1) AMOUNTS.—A subscription contract under 
4
this section shall be for the sale to the Secretary of 
5
any quantity of the antimicrobial drug needed over 
6
the term of the contract under paragraph (2), at an 
7
agreed upon price, for a total projected amount de-
8
termined by the Secretary that is not less than 
9
$750,000,000 and not more than $3,000,000,000, 
10
adjusted for inflation, accounting for the favored 
11
characteristics of the drug, as determined by the 
12
Secretary, in consultation with the Committee, under 
13
subsection (a)(2), and shall be allocated from the 
14
amount made available under section 6(a). Not later 
15
than 6 months after the subscription contract is 
16
granted under subsection (a), the Secretary shall 
17
provide payments for purchased drugs in install-
18
ments established by the Secretary in consultation 
19
with the sponsor of the antimicrobial drug and in ac-
20
cordance with subsection (d)(3). Funds received by 
21
the sponsor may be used to support criteria quali-
22
fication under subsection (b), the completion of post-
23
marketing clinical studies, manufacturing, and other 
24
23:19 Dec 21, 2020
H8920
20 
•HR 8920 IH
preclinical and clinical activities agreed to by the 
1
Secretary and sponsor in the contract. 
2
(2) TERMS.— 
3
(A) INITIAL TERM.—The initial term of a 
4
contract under this subsection shall be no less 
5
than 5 years or greater than the greater of 10 
6
years or the remaining period of time during 
7
which the sponsor has patent protections or a 
8
remaining exclusivity period with respect to the 
9
antimicrobial drug in the United States, as list-
10
ed in the publication of the Food and Drug Ad-
11
ministration entitled ‘‘Approved Drug Products 
12
with Therapeutic Equivalence Evaluations’’. 
13
Payments may be in equal annual installments 
14
with the option to redeem 50 percent of the last 
15
year’s reimbursement in year 1 of the contract 
16
in order to offset costs of establishing manufac-
17
turing capacity, or another subscription ar-
18
rangement to which the Secretary and sponsor 
19
agree. Subscription contracts shall remain in ef-
20
fect for such period even if the infection treated 
21
by such antimicrobial drug is later removed 
22
from the list of infections under section 2(c)(1). 
23
(B) EXTENSION
OF
CONTRACTS.—The 
24
Secretary may extend subscription contracts be-
25
23:19 Dec 21, 2020
H8920
21 
•HR 8920 IH
yond the initial contract period with a generic 
1
or biosimilar brand manufacturer of the anti-
2
microbial drug receiving a subscription contract 
3
or the original drug manufacturer. A single 
4
contract extension may be in effect not later 
5
than the date on which all periods of exclusivity 
6
granted by the Food and Drug Administration 
7
expire and shall be in an amount not to exceed 
8
$25,000,000 per year. All other terms of an ex-
9
tended contract shall be the same as the terms 
10
of the initial contract. The total amount of 
11
funding used on such contract extensions shall 
12
be no more than $1,000,000,000, and shall be 
13
allocated from the amount made available under 
14
section 6. 
15
(C) MODIFICATION OF CONTRACTS.—The 
16
Secretary or sponsor, every 2 years after the 
17
start of the contract period under this sub-
18
section, may request a modification of the 
19
amount of the contract based on information 
20
that adjusts favored characteristics in section 
21
2(c)(2). 
22
(3) ADJUSTMENT.—In the case of an anti-
23
microbial drug that received a transitional subscrip-
24
tion contract under section 2(f), the amount of a 
25
23:19 Dec 21, 2020
H8920
22 
•HR 8920 IH
subscription contract for such drug under this sec-
1
tion shall be reduced by the amount of the transi-
2
tional subscription contract under such section 2(f) 
3
for such drug. 
4
(d) ANNUAL ANTIMICROBIAL DRUG SPONSOR REV-
5
ENUE LIMITATIONS.— 
6
(1) REPORTING REQUIREMENT.— 
7
(A) IN GENERAL.—Not later than a date 
8
determined appropriate by the Secretary fol-
9
lowing the end of each calendar year, the head 
10
(or a designee of such head) of each Federal 
11
agency carrying out a specified government pro-
12
gram shall, in accordance with this paragraph, 
13
report to the Secretary of Health and Human 
14
Services the total prescription drug sales for 
15
each applicable antimicrobial drug under con-
16
tract with respect to such program for such cal-
17
endar year. 
18
(B) MEDICARE
PART
D
PROGRAM.—For 
19
purposes of subparagraph (A), the Secretary 
20
shall report, for each applicable antimicrobial 
21
drug covered under part D of title XVIII of the 
22
Social Security Act (42 U.S.C. 1395w–101 et 
23
seq.), the product of— 
24
23:19 Dec 21, 2020
H8920
23 
•HR 8920 IH
(i) the per-unit ingredient cost, as re-
1
ported to the Secretary by prescription 
2
drug plans and Medicare Advantage pre-
3
scription drug plans, minus any per-unit 
4
rebate, discount, or other price concession 
5
provided, as reported to the Secretary by 
6
the prescription drug plans and the Medi-
7
care Advantage prescription drug plans; 
8
and 
9
(ii) the number of units of such appli-
10
cable antimicrobial drug paid for under 
11
such part D. 
12
(C) MEDICARE
PART
B
PROGRAM.—For 
13
purposes of subparagraph (A), the Secretary 
14
shall report, for each applicable antimicrobial 
15
drug covered under part B of title XVIII of the 
16
Social Security Act (42 U.S.C. 1395j et seq.), 
17
the product of— 
18
(i) the per-unit average sales price (as 
19
defined in section 1847A(c) of such Act 
20
(42 U.S.C. 1395w–3a(c))) or the per-unit 
21
payment rate under such part B for a sep-
22
arately paid prescription drug without a 
23
reported average sales price; and 
24
23:19 Dec 21, 2020
H8920
24 
•HR 8920 IH
(ii) the number of units of such appli-
1
cable antimicrobial drug paid for under 
2
such part B. 
3
(D) MEDICARE PART A PROGRAM.— 
4
(i) IN
GENERAL.—For purposes of 
5
subparagraph (A), the Secretary shall re-
6
port, for each applicable antimicrobial drug 
7
covered under part A of title XVIII of the 
8
Social Security Act (42 U.S.C. 1395c et 
9
seq.), the product of— 
10
(I) the per-unit price under such 
11
part A for the antimicrobial drug; and 
12
(II) the number of units of such 
13
antimicrobial drug paid for under 
14
such part A. 
15
(ii) SPECIAL RULE.—For purposes of 
16
clause (i), the Secretary shall establish a 
17
process for determining the units and the 
18
allocated price for those prescription drugs 
19
that are not separately payable or for 
20
which National Drug Codes are not re-
21
ported in the diagnosis-related groups. 
22
(E) MEDICAID PROGRAM.—Under the au-
23
thority of section 1902(a)(6) of the Social Secu-
24
rity Act (42 U.S.C. 1396a(a)(6)), the Secretary 
25
23:19 Dec 21, 2020
H8920
25 
•HR 8920 IH
shall require each State that makes medical as-
1
sistance available under the State Medicaid pro-
2
gram for an applicable antimicrobial drug (in-
3
cluding, if applicable, any such drug which is a 
4
covered outpatient drug under a rebate agree-
5
ment entered into under section 1927 of such 
6
Act (42 U.S.C. 1396r–8)) to report to the Sec-
7
retary, not later than the date established 
8
under subparagraph (A), for each dosage form 
9
and strength and package size of each such 
10
drug dispensed during the preceding calendar 
11
year under the State Medicaid program, the 
12
amount equal to— 
13
(i) the product of— 
14
(I) the per-unit ingredient cost 
15
paid by the State for each such drug; 
16
and 
17
(II) the number of units of such 
18
drug paid for under the State Med-
19
icaid program; minus 
20
(ii) any discounts or other price con-
21
cessions provided and rebates paid to the 
22
State with respect to such drug and such 
23
calendar year (including rebates paid 
24
under a rebate agreement under section 
25
23:19 Dec 21, 2020
H8920
26 
•HR 8920 IH
1927 of such Act (42 U.S.C. 1396r–8) and 
1
any State supplemental rebates paid under 
2
a supplemental rebate agreement). 
3
(F) DEPARTMENT
OF
VETERANS
AF-
4
FAIRS.—For purposes of subparagraph (A), the 
5
Secretary of Veterans Affairs shall report the 
6
total amount paid for each applicable anti-
7
microbial drug procured by the Veterans Health 
8
Administration for individuals who receive 
9
health care from the Administration. 
10
(G) DEPARTMENT
OF
DEFENSE
AND 
11
TRICARE PROGRAM.—For purposes of subpara-
12
graph (A), the Secretary of Defense shall report 
13
the sum of— 
14
(i) the total amount paid for each ap-
15
plicable antimicrobial drug procured by the 
16
Department of Defense for individuals who 
17
receive health care from the Department; 
18
and 
19
(ii) for each applicable antimicrobial 
20
drug dispensed under the TRICARE retail 
21
pharmacy program, the product of— 
22
(I) the per-unit ingredient cost, 
23
minus any per-unit rebate paid by the 
24
covered entity; and 
25
23:19 Dec 21, 2020
H8920
27 
•HR 8920 IH
(II) the number of units of such 
1
applicable antimicrobial drug dis-
2
pensed under such program. 
3
(H) DEPARTMENT
OF
HOMELAND
SECU-
4
RITY.—For purposes of subparagraph (A), the 
5
Secretary of Homeland Security shall report the 
6
total amount paid for each applicable anti-
7
microbial drug procured by the Department of 
8
Homeland Security for individuals who receive 
9
health care through a program carried out by 
10
the Department. 
11
(I) BUREAU OF PRISONS.—For purposes of 
12
subparagraph (A), the Director of the Bureau 
13
of Prisons shall report the total amount paid 
14
for each applicable antimicrobial drug procured 
15
by the Bureau of Prisons for individuals who 
16
receive health care through the Bureau. 
17
(J) INDIAN HEALTH SERVICE.—For pur-
18
poses of subparagraph (A), the Secretary, act-
19
ing through the Indian Health Service, shall re-
20
port the total amount paid for each applicable 
21
antimicrobial drug procured by the Service for 
22
individuals who receive health care through the 
23
Service. 
24
23:19 Dec 21, 2020
H8920
28 
•HR 8920 IH
(2) GUIDANCE.—Not later than 1 year after 
1
the date of enactment of this Act, the Secretary 
2
shall publish guidance to assist the heads (or des-
3
ignees) of Federal agencies carrying out specified 
4
government programs in carrying out the require-
5
ments under this section. 
6
(3) SUBSCRIPTION CONTRACT ADJUSTMENT.— 
7
Pursuant to the contract entered into under this sec-
8
tion with respect to an applicable antimicrobial drug, 
9
for each year of the term of such contract, the Sec-
10
retary shall subtract from the payment installments 
11
determined for such contract under subsection (c)(1) 
12
for such year the revenue of the sponsor of such 
13
drug from the previous year from sales of the appli-
14
cable antimicrobial drug reported under paragraph 
15
(1) for specified government programs. 
16
(4) DEFINITIONS.—In this subsection: 
17
(A) APPLICABLE ANTIMICROBIAL DRUG.— 
18
The term ‘‘applicable antimicrobial drug’’ 
19
means an antimicrobial drug for which the 
20
sponsor of such drug receives a subscription 
21
contract under subsection (a). 
22
(B) SPECIFIED GOVERNMENT PROGRAM.— 
23
The term ‘‘specified government program’’ 
24
means— 
25
23:19 Dec 21, 2020
H8920
29 
•HR 8920 IH
(i) the Medicare part D program 
1
under part D of title XVIII of the Social 
2
Security Act (42 U.S.C. 1395w–101 et 
3
seq.); 
4
(ii) the Medicare Part B program 
5
under part B of such title XVIII (42 
6
U.S.C. 1395j et seq.); 
7
(iii) the Medicare Part A program 
8
under part A of such title XVIII (42 
9
U.S.C. 1395c et seq.); 
10
(iv) the Medicaid program established 
11
under title XIX of the Social Security Act 
12
(42 U.S.C. 1396 et seq.) and includes, 
13
with respect to a State, any waiver in ef-
14
fect with respect to such program; 
15
(v) any program under which pre-
16
scription drugs are procured by the De-
17
partment of Veterans Affairs; 
18
(vi) any program under which brand-
19
ed prescription drugs are procured by the 
20
Department of Defense; 
21
(vii) the TRICARE retail pharmacy 
22
program under section 1074g of title 10, 
23
United States Code; 
24
23:19 Dec 21, 2020
H8920
30 
•HR 8920 IH
(viii) any program under which pre-
1
scription drugs are procured by the De-
2
partment of Homeland Security; 
3
(ix) any program under which pre-
4
scription drugs are procured by the Bu-
5
reau of Prisons; or 
6
(x) any program under which pre-
7
scription drugs are procured by the Indian 
8
Health Service. 
9
(e) FAILURE TO ADHERE
TO TERMS.—The Sec-
10
retary shall cease any payment installments under a con-
11
tract under this section if— 
12
(1) the sponsor— 
13
(A) permanently withdraws the anti-
14
microbial drug from the market in the United 
15
States; 
16
(B) fails to meet criteria under subsection 
17
(b); or 
18
(C) does not complete a postmarket study 
19
required by the Food and Drug Administration 
20
during the length of the term of the contract; 
21
or 
22
(2) the annual international and private insur-
23
ance market revenues with respect to an anti-
24
microbial drug (not counting any subscription reve-
25
23:19 Dec 21, 2020
H8920
31 
•HR 8920 IH
nues from any source pursuant to a contract under 
1
this section or other international or private entities) 
2
exceed 5 times the average annual amount of the 
3
subscription contract paid by the Secretary as cer-
4
tified by the sponsor annually. 
5
(f) PRIVATE PAYER
AND INTERNATIONAL PAYER 
6
PARTICIPATION.—The Secretary shall make efforts to in-
7
crease the participation of domestic private payors and 
8
international payors in subscription contracts or other 
9
types of pull incentives that are similar to the subscription 
10
contracts authorized under this section. 
11
SEC. 5. ENCOURAGING APPROPRIATE USE OF ANTIBIOTICS 
12
AND COMBATING RESISTANCE. 
13
(a) ESTABLISHMENT
OF HOSPITAL GRANT PRO-
14
GRAM.— 
15
(1) IN GENERAL.—Not later than 1 year after 
16
the date of enactment of this Act, the Secretary and 
17
the Director of the Centers for Disease Control and 
18
Prevention shall coordinate with the Administrator 
19
of the Health Resources and Services Administra-
20
tion, the Administrator of the Centers for Medicare 
21
& Medicaid Services, the National Coordinator for 
22
Health Information Technology, and other relevant 
23
agencies, to establish a grant program under the 
24
23:19 Dec 21, 2020
H8920
32 
•HR 8920 IH
Centers for Disease Control and Prevention to sup-
1
port hospital and other inpatient facility efforts— 
2
(A) to judiciously use antimicrobial drugs, 
3
such as by establishing or implementing appro-
4
priate use programs, including infectious dis-
5
ease telehealth programs, using appropriate di-
6
agnostic tools, partnering with academic hos-
7
pitals, increasing health care-associated infec-
8
tion reporting, and monitoring antimicrobial re-
9
sistance; and 
10
(B) 
to 
participate 
in 
the 
National 
11
Healthcare Safety Network Antimicrobial Use 
12
and Resistance Module or the Emerging Infec-
13
tions Program Healthcare-Associated Infections 
14
Community Interface activity of the Centers for 
15
Disease Control and Prevention or a similar re-
16
porting program, as specified by the Secretary, 
17
relating to antimicrobial drugs. 
18
(2) 
PRIORITIZATION.—In 
awarding 
grants 
19
under paragraph (1), the Secretary shall prioritize 
20
hospitals without an existing program to judiciously 
21
use antimicrobial drugs, subsection (d) hospitals (as 
22
defined in subparagraph (B) of section 1886(d)(2) 
23
of 
the 
Social 
Security 
Act 
(42 
U.S.C. 
24
1395ww(d)(2))) that are located in rural areas (as 
25
23:19 Dec 21, 2020
H8920
33 
•HR 8920 IH
defined in subparagraph (D) of such section), crit-
1
ical 
access 
hospitals 
(as 
defined 
in 
section 
2
1861(mm)(1) 
of 
such 
Act 
(42 
U.S.C. 
3
1395x(mm)(1))), 
hospitals 
serving 
Tribal-popu-
4
lations, and safety-net hospitals. 
5
(3) FUNDING.—Of the amounts appropriated 
6
under section 6, the Secretary shall reserve 
7
$500,000,000 to carry out this subsection. 
8
(b) SURVEILLANCE AND REPORTING OF ANTIBIOTIC 
9
USE AND RESISTANCE.— 
10
(1) 
IN
GENERAL.—The 
Secretary, 
acting 
11
through the Director of the Centers for Disease 
12
Control and Prevention, shall use the National 
13
Healthcare Safety Network and other appropriate 
14
surveillance systems to assess— 
15
(A) appropriate conditions, outcomes, and 
16
measures causally related to antibacterial resist-
17
ance, including types of infections, the causes 
18
for infections, and whether infections are ac-
19
quired in a community or hospital setting, in-
20
creased lengths of hospital stay, increased costs, 
21
and rates of mortality; and 
22
(B) changes in bacterial resistance to anti-
23
microbial drugs in relation to patient outcomes, 
24
including changes in percent resistance, preva-
25
23:19 Dec 21, 2020
H8920
34 
•HR 8920 IH
lence of antibiotic-resistant infections, and other 
1
such changes. 
2
(2) ANTIBIOTIC
USE
DATA.—The Secretary, 
3
acting through the Director of the Centers for Dis-
4
ease Control and Prevention, shall work with Fed-
5
eral agencies (including the Department of Veterans 
6
Affairs, the Department of Defense, the Department 
7
of Homeland Security, the Bureau of Prisons, the 
8
Indian Health Service, and the Centers for Medicare 
9
& Medicaid Services), private vendors, health care 
10
organizations, pharmacy benefit managers, and 
11
other entities as appropriate to obtain reliable and 
12
comparable human antibiotic drug consumption data 
13
(including, as available and appropriate, volume an-
14
tibiotic distribution data and antibiotic use data, in-
15
cluding prescription data) by State or metropolitan 
16
areas. 
17
(3) ANTIBIOTIC
RESISTANCE
TREND
DATA.— 
18
The Secretary, acting through the Director of the 
19
Centers for Disease Control and Prevention, shall in-
20
tensify and expand efforts to collect antibiotic resist-
21
ance data and encourage adoption of the antibiotic 
22
resistance and use module within the National 
23
Healthcare Safety Network among all health care fa-
24
cilities across the continuum of care, including, as 
25
23:19 Dec 21, 2020
H8920
35 
•HR 8920 IH
appropriate, acute care hospitals, dialysis facilities, 
1
nursing homes, ambulatory surgical centers, and 
2
other ambulatory health care settings in which anti-
3
microbial drugs are routinely prescribed. The Sec-
4
retary shall seek to collect such data from electronic 
5
medication administration reports and laboratory 
6
systems to produce the reports described in para-
7
graph (4). 
8
(4) PUBLIC AVAILABILITY OF DATA.—The Sec-
9
retary, acting through the Director of the Centers 
10
for Disease Control and Prevention, shall, for the 
11
purposes of improving the monitoring of important 
12
trends in patient outcomes in relation to anti-
13
bacterial resistance— 
14
(A) make the data derived from surveil-
15
lance under this subsection publicly available 
16
through reports issued on a regular basis that 
17
is not less than annually; and 
18
(B) examine opportunities to make such 
19
data available in near real time. 
20
SEC. 6. APPROPRIATIONS. 
21
(a) IN GENERAL.—To carry out this Act, there are 
22
hereby appropriated to the Secretary, out of amounts in 
23
the 
Treasury 
not 
otherwise 
appropriated, 
24
23:19 Dec 21, 2020
H8920
36 
•HR 8920 IH
$11,000,000,000, for fiscal year 2021, to remain available 
1
until expended. 
2
(b) EMERGENCY DESIGNATION.— 
3
(1) IN
GENERAL.—The amounts provided by 
4
this section are designated as an emergency require-
5
ment pursuant to section 4(g) of the Statutory Pay- 
6
As-You-Go Act of 2010 (2 U.S.C. 933(g)). 
7
(2) DESIGNATION IN SENATE.—In the Senate, 
8
this section is designated as an emergency require-
9
ment pursuant to section 4112(a) of H. Con. Res. 
10
71 (115th Congress), the concurrent resolution on 
11
the budget for fiscal year 2018. 
12
SEC. 7. STUDIES AND REPORTS. 
13
(a) IN GENERAL.—Not later than 6 years after the 
14
date of enactment of this Act, the Comptroller General 
15
of the United States shall complete a study on the effec-
16
tiveness of this Act in developing priority antimicrobial 
17
drugs. Such study shall examine the indications for, usage 
18
of, development of resistance with respect to, and private 
19
and societal value of critical need antimicrobial drugs, and 
20
the impact of the programs under this Act on patients 
21
and markets of critical need antimicrobial drugs. The 
22
Comptroller General shall report to the Committee on 
23
Health, Education, Labor, and Pensions of the Senate and 
24
23:19 Dec 21, 2020
H8920
37 
•HR 8920 IH
the Committee on Energy and Commerce of the House 
1
of Representatives on the findings of such study. 
2
(b) ANTIBIOTIC USE IN THE UNITED STATES; AN-
3
NUAL REPORTS.—The Director of the Centers for Disease 
4
Control and Prevention shall, each year, update the report 
5
entitled ‘‘Antibiotic Use in the United States’’ to include 
6
updated information on progress and opportunities with 
7
respect to data, programs, and resources for prescribers 
8
to promote appropriate use of antimicrobial drugs. 
9
(c) REPORTS
ON ANTIFUNGAL RESISTANCE
AND 
10
ANTIMICROBIAL PROPHYLACTICS.—Not later than 3 years 
11
after the date of enactment of this Act, the Director of 
12
the Centers for Disease Control and Prevention shall pub-
13
lish— 
14
(1) a report on antifungal resistance in the 
15
United States; and 
16
(2) a report on antimicrobial prophylactics. 
17
SEC. 8. DEFINITIONS. 
18
In this Act— 
19
(1) the term ‘‘antimicrobial drug’’— 
20
(A) subject to subparagraph (B), means— 
21
(i) an antibiotic drug, as defined in 
22
section 201(jj) of the Federal Food, Drug, 
23
and Cosmetic Act (21 U.S.C. 321(jj)); or 
24
23:19 Dec 21, 2020
H8920
38 
•HR 8920 IH
(ii) a biological product, as defined in 
1
section 351(i) of the Public Health Service 
2
Act (42 U.S.C. 262(i)), that exhibits anti-
3
microbial activity; and 
4
(B) excludes— 
5
(i) any antifungal drug; and 
6
(ii) any vaccine; 
7
(2) the term ‘‘Committee’’ means the Com-
8
mittee on Critical Need Antimicrobials established 
9
under section 2; and 
10
(3) the term ‘‘Secretary’’ means the Secretary 
11
of Health and Human Services. 
12
Æ 
23:19 Dec 21, 2020
H8920
